BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study
Rosa Ayala(Hospital Universitario 12 De Octubre), David Lavie(Hadassah Medical Center), Oriana Esposito, Vivian Shan(Bristol-Myers Squibb (United States)), Maan Alwan, Indu Raman(Epworth Hospital), Shodeinde Coker(Bristol-Myers Squibb (United States)), Chun Yew Fong(Olivia Newton-John Cancer Wellness & Research Centre), Palanikumar Ravindran(Bristol-Myers Squibb (United States)), Nieves López‐Muñoz, Vincent Ribrag(Institut Gustave Roussy), Costas K. Yannakou(Epworth Hospital), Massimiliano Bonifacio(University of Verona), Christopher Tehlirian(Bristol-Myers Squibb (United States)), Sharmila Das(Bristol-Myers Squibb (United States)), Alessandra Tucci(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Zariana Nikolova(Bristol-Myers Squibb (Switzerland)), Guan Wang(Sichuan University), Yü Liu(Tianshui Normal University), Bin Wu(Jiangsu Provincial Center for Disease Control and Prevention), Adi Shacham Abulafia(Tel Aviv University), Jean‐Jacques Kiladjian(Délégation Paris 5), Henry Chang(Bristol-Myers Squibb (United States)), Yulia Volchek(Assaf Harofeh Medical Center)
Cited by 4
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
|New England Journal of Medicine|2002|1.2k
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
|Blood|2008|568